91 related articles for article (PubMed ID: 28844386)
1. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.
Zhao H; Anyika M; Girgis A; Blagg BS
Bioorg Med Chem Lett; 2014 Aug; 24(15):3633-7. PubMed ID: 24953820
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.
Garg G; Zhao H; Blagg BS
Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946
[TBL] [Abstract][Full Text] [Related]
3. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity.
Zhang Z; Banerjee M; Davis RE; Blagg BSJ
Bioorg Med Chem Lett; 2019 Nov; 29(22):126676. PubMed ID: 31591016
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
Kusuma BR; Duerfeldt AS; Blagg BS
Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
[TBL] [Abstract][Full Text] [Related]
6. Exploiting polarity and chirality to probe the Hsp90 C-terminus.
Forsberg LK; Davis RE; Wimalasena VK; Blagg BSJ
Bioorg Med Chem; 2018 Jul; 26(12):3096-3110. PubMed ID: 29720349
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
[TBL] [Abstract][Full Text] [Related]
8. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.
Forsberg LK; Anyika M; You Z; Emery S; McMullen M; Dobrowsky RT; Blagg BSJ
Eur J Med Chem; 2018 Jan; 143():1428-1435. PubMed ID: 29137866
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives.
Sellers RP; Alexander LD; Johnson VA; Lin CC; Savage J; Corral R; Moss J; Slugocki TS; Singh EK; Davis MR; Ravula S; Spicer JE; Oelrich JL; Thornquist A; Pan CM; McAlpine SR
Bioorg Med Chem; 2010 Sep; 18(18):6822-56. PubMed ID: 20708938
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity.
Zhang Z; You Z; Dobrowsky RT; Blagg BSJ
Bioorg Med Chem Lett; 2018 Sep; 28(16):2701-2704. PubMed ID: 29759728
[TBL] [Abstract][Full Text] [Related]
11. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain.
Kumar Mv V; Ebna Noor R; Davis RE; Zhang Z; Sipavicius E; Keramisanou D; Blagg BSJ; Gelis I
Medchemcomm; 2018 Aug; 9(8):1323-1331. PubMed ID: 30151087
[TBL] [Abstract][Full Text] [Related]
12. Development of Noviomimetics as C-Terminal Hsp90 Inhibitors.
Anyika M; McMullen M; Forsberg LK; Dobrowsky RT; Blagg BS
ACS Med Chem Lett; 2016 Jan; 7(1):67-71. PubMed ID: 26819668
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.
Mbofung RM; McKenzie JA; Malu S; Zhang M; Peng W; Liu C; Kuiatse I; Tieu T; Williams L; Devi S; Ashkin E; Xu C; Huang L; Zhang M; Talukder AH; Tripathi SC; Khong H; Satani N; Muller FL; Roszik J; Heffernan T; Allison JP; Lizee G; Hanash SM; Proia D; Amaria R; Davis RE; Hwu P
Nat Commun; 2017 Sep; 8(1):451. PubMed ID: 28878208
[TBL] [Abstract][Full Text] [Related]
14. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients.
Parker WP; Smelser W; Lee EK; Habermann EB; Thapa P; Zaid HB; Frank I; Griebling TL; Tollefson MK; Thompson RH; Holzbeierlein JM; Karnes RJ; Boorjian SA
Clin Genitourin Cancer; 2017 Aug; ():. PubMed ID: 28844793
[TBL] [Abstract][Full Text] [Related]
15. Development of Hsp90 C-terminal inhibitors with noviomimetics that manifest anti-proliferative activities.
Amatya E; Subramanian C; Cohen MS; Blagg BSJ
RSC Med Chem; 2024 Mar; 15(3):888-894. PubMed ID: 38516588
[TBL] [Abstract][Full Text] [Related]
16. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract][Full Text] [Related]
17. General Structural and Functional Features of Molecular Chaperones.
Edkins AL; Boshoff A
Adv Exp Med Biol; 2021; 1340():11-73. PubMed ID: 34569020
[TBL] [Abstract][Full Text] [Related]
18. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
